Downloaded 62 times
Uploaded byGenomeInABottle
150224 giab 30 min generic slides
This document summarizes the work of the Genome in a Bottle Consortium to develop reference materials for evaluating the accuracy of whole genome sequencing. It finds that different sequencing platforms and bioinformatics programs often disagree on called variants. The Consortium is developing well-characterized human genomes that will serve as standards, including the genome of individual NA12878. The goal is to assign confidence levels to called variants and provide integrated variant calls across multiple datasets to help benchmark sequencing accuracy and evaluate sequencing performance in different genomic and clinical contexts.
More Related Content
Similar to 150224 giab 30 min generic slides
150224 giab 30 min generic slides
- 1. Genome in aBottle: So you’ve sequenced a genome – how well did you do? February 2015 Justin Zook, Marc Salit, and the Genome in a Bottle Consortium
- 2. Whole genome sequencingtechnologies disagree about 100,000’s of variants 3,198,316 (80.05%) 125,574 (3.14%) Platform #1 Platform #2 Platform #3 230,311 (5.76%) 121,440 (3.04%) 208,038 (5.21%) 71,944 (1.80%) 39,604 (0.99%) # SNPs (% of SNPs detected by any platform)
- 3. Bioinformatics programs alsodisagree O’Rawe et al. Genome Medicine 2013, 5:28
- 4. NIST-hosted Genome in aBottle Consortium • Infrastructure for performance assessment of NGS – support science-based regulatory oversight • No widely accepted set of metrics to characterize the fidelity of variant calls from NGS… • Genome in a Bottle Consortium is developing standards to address this… – well-characterized human genomes as Reference Materials (RMs) • characterized and disseminated by NIST – tools and methods to use these RMs • Global Alliance for Genomics and Health Benchmarking Team http://genomeinabottle.org
- 5. Genome in aBottle Consortium Development • NIST met with sequencing technology developers to assess standards needs – Stanford, June 2011 • Open, exploratory workshop – ASHG, Montreal, Canada – October 2011 • Small, invitational workshop at NIST to develop consortium for human genome reference materials – FDA, NCBI, NHGRI, NCI, CDC, Wash U, Broad, technology developers, clinical labs, CAP, PGP, Partners, ABRF, others – developed draft work plan – April 2012 • Open, public meetings of GIAB – August 2012 at NIST – March 2013 at Xgen – August 2013 at NIST – January 2014 at Stanford – August 2014 at NIST – January 2015 at Stanford • Website – www.genomeinabottle.org
- 6. Others working inthis space… Well-characterized genomes • Illumina Platinum Genomes • CDC GeT-RM • Korean Genome Project • Human Longevity, Inc. • Hyditaform mole haploid cell line • Genome Reference Consortium Performance Metrics • Global Alliance for Genomics and Health Benchmarking Team • NCBI/CDC GeT-RM Browser • GCAT website
- 7. NIST Plays aRole in the First FDA Authorization for Next-Generation Sequencer November 20, 2013
- 8. Measurement Process Sample gDNA isolation LibraryPrep Sequencing Alignment/Mapping Variant Calling Confidence Estimates Downstream Analysis • gDNA reference materials will be developed to characterize performance of a part of process – materials will be certified for their variants against a reference sequence, with confidence estimates genericmeasurementprocess Analytical steps Pre-Analytical steps Clinical Interpretation
- 9. • NIST workedwith GIAB to select genomes • Current genomes – NA12878 HapMap sample as Pilot sample • part of 17-member pedigree – 2 trios from PGP • Ashkenazim • Asian 12889 12890 12891 12892 12877 12878 12879 12880 12881 12882 12883 12884 12885 1288712886 12888 12893 CEPH Utah Pedigree 1463 Putting “Genomes” in Bottles 11 children
- 10. NIST Human GenomeRMs in the pipeline • All 10 ug samples of DNA isolated from multistage large growth cell cultures – all are intended to act as stable, homogeneous references suitable for use in regulated applications – all genomes also available from Coriell repository • Pilot Genome – ~8400 tubes • Ashkenazim Jewish Trio – ~10000 son; ~2500 each parent • Asian Trio – ~10000 son; parents not yet planned as NIST RM
- 11. Goals for Datato Accompany RM • ~0 false positive AND false negative calls in confident regions • Include as much of the genome as possible in the confident regions (i.e., don’t just take the intersection) • Avoid bias towards any particular platform – take advantage of strengths of each platform • Avoid bias towards any particular bioinformatics algorithms 11
- 12. Pilot Genome: Integrate12 14 Datasets from 5 platforms 12
- 13. Dataset#1Dataset#2Dataset#3 Annotation #1 Histogram (e.g., coverage) Dataset#1Dataset#2Dataset#3 Annotation#2 Histogram (e.g., strand bias) Site A Site B Potential Bias Site C Dataset Site A Site B Site C Dataset #1 0/0 0/0 1/1 Dataset #2 0/1 0/1 1/1 Dataset #3 0/0 0/1 1/1 Integration 0/0 0/1 Uncer- tain Candidate variants Concordant variants Find characteristics of bias Arbitrate using evidence of bias Confidence Level Integration Methods to Establish Benchmark Variant Calls
- 14. Integration Methods toEstablish Benchmark Variant Calls Candidate variants Concordant variants Find characteristics of bias Arbitrate using evidence of bias Confidence Level Zook et al., Nature Biotechnology, 2014.
- 15. Assigning confidence togenotypes High-confidence sites • Sequencing/bioinformatics methods agree or we understand the biases causing disagreement • At least some methods have no evidence of bias • Inherited as expected Less confident sites • In a region known to be difficult for current technologies • State reasons for lower confidence • If a site is near a low confidence site, make it low confidence
- 16. Challenges with assessing performance •All variant types are not equal • All regions of the genome are not equal • Labeling difficult variants as uncertain leads to higher apparent accuracy when assessing performance • Genotypes fall in 3+ categories (not positive/negative) – standard diagnostic accuracy measures not well posed 16
- 17. Challenge in variantcomparison: Complex variants have multiple correct representations BWA ssaha2 CGTools Novo- align Ref: T insertion TCTCT insertion 17 FP SNPs FP MNPs FP indels Traditional comparison 0.38% (610) 100% (915) 6.5% (733) Comparison with realignment 0.15% (249) 4.2% (38) 2.6% (298)
- 18. Global Alliance forGenomics and Health Benchmarking Task Team • Formed June 2014 to develop methods and tools for comparing variant calls to a benchmark • Developed standardized definitions for performance metrics like TP, FP, and FN. • Initial focus on germline SNPs/indels • Developing benchmarking tools • Comparison engine • Pluggable web interface with modules for: • Reporting/calculation of metrics • Visualization/user interface • Working with Genome in a Bottle Consortium to host data and calls from their well-characterized genomes www.bioplanet.com/gcat Example User Interface
- 19. Stratifying Performance • Measureperformance for different types of variants in different sequence contexts – Types of variants • SNPs • indels of different sizes • complex variants • structural variants – Sequence contexts • Homopolymers, • STRs • Duplications – Functional context • Exome vs genome, etc – Data characteristics • Coverage • Mapping quality • Challenge of smaller gene panels vs genome sequencing – one RM may not have a sufficient number of examples of different classes of variants or sequence contexts – likely need more samples with specific types of variants
- 20. NCBI/CDC GeT-RM Browser •http://www.ncbi.nlm.nih.gov/variation/tools/get-rm/ • Allows visualization of questionable calls
- 21. Initial uses ofhigh-confidence NIST- GIAB genotypes for NA12878 • NIST have released several versions of high- confidence genotypes for its pilot RM • These data are presently being used for benchmarking – prior to release of RMs – SNPs & indels • ~77% of the genome
- 22. Using Genome ina Bottle calls to benchmark clinical exome sequencing at Mount Sinai School of Medicine “We evaluate a set of NA12878 technical replicates against GIAB for each new pipeline version.”
- 23. Benchmarking somatic variantcalling at Qiagen
- 24. Implications of TechnicalAccuracy in Medical Genome Sequencing • Collaboration with Euan Ashley group at Stanford • What is accuracy for functional variants? • How much of the exome falls in high confidence regions? • “Black list” in databases • Sensitivity – WExS (95%) < WGS (98%) • especially splicing – genome < nonsyn < syn – Most exome FNs caused by low coverage – Most WGS FNs cause by filtering • Only 81 % of ClinVar pathogenic or likely pathogenic SNPs fall in high-confidence regions – Lots of work to do!
- 25. Overview of NISTRM Development Genome(s) Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 HG- 001/NA1287 8 (“Pilot” Genome) Release NIST RM8398; Preliminary large deletions Refined Structural Variants HG-002 to HG-004 (Ashkenazim trio) Illumina, Complete Genomics, Ion, BioNano, homogeneity /stability Preliminary SNPs/indels; 120x-150x PacBio data; “moleculo”; mate-pair; CG-LFR Refined SNPs/indels ; Preliminary SVs Refined Structural Variants NIST RMs 8391/839 2 release HG-005 (son in Asian trio) Illumina, Complete Genomics, Ion, BioNano, homogeneity /stability “moleculo”; mate-pair; CG-LFR Preliminary SNPs/indels Refined SNPs/indels; Refined Structural Variants NIST RM8393 release
- 26. Ashkenazim Jewish PGPRM Trio Dataset Characteristics Coverage Availability Good for… Illumina Paired- end 150x150bp ~300x/individu al Fastq on ftp SNPs/indels/so me SVs Illumina Long Mate pair ~6000 bp insert ~40x/individual Feb-Mar 2015 SVs Illumina “moleculo” Custom library ~30x by long fragments Feb-Mar 2015 SVs/phasing/as sembly Complete Genomics 100x/individual On ftp SNPs/indels/so me SVs Complete Genomics LFR ?? SNPs/indels/ph asing Ion Proton Exome 1000x/individu al On SRA SNPs/indels in exome BioNano Genomics Feb 2015 SVs/assembly PacBio ~10kb reads ~120-150x on AJ trio Finished ~Mar 2015 SVs/phasing/as sembly/STRs
- 27. Asian PGP trio •Similar sequencing to Ashkenazim trio except for PacBio • Only son will be NIST RM
- 28. Future Directions Germline mutations •Difficult regions/variants – Long-read technologies – Forming an analysis group • Tools for assessing performance – How to stratify performance and understand biases? Somatic mutations • Pilot interlaboratory study to assess comparability of spike-ins • Commercial members developing FFPE cell lines • Participants interested in mixing different RMs
- 29. How to getinvolved • Use our integrated SNP/indel genotypes for NA12878 and give us feedback – Cells and DNA currently available from Coriell – NIST RM available April 2015 • Join our new Analysis group – Use Long-read technologies – Structural Variant calls – De novo assembly – Help create the best-ever characterized trio • Attend our biannual workshops (January in CA, August in MD) • Develop tools/metrics with Global Alliance for Genomics and Health Benchmarking Team
- 30. Acknowledgments • FDA –Elizabeth Mansfield, HPC staff • HSPH • GCAT - David Mittelman, Jason Wang • Francisco De La Vega • Illumina - Mike Eberle • Personalis - Deanna Church • NCBI – Chunlin Xiao • Celera - Andrew Grupe • Genome in a Bottle – www.genomeinabottle.org – New members welcome! – Sign up for email newsletters – jzook@nist.gov